** Vigil Neuroscience shares VIGL.O jump 245% to $8 premarket as Sanofi to acquire firm in $470 million deal to boost its neurological pipeline
** Sanofi would pay $8 per share to Vigil shareholders, who would also be eligible for a contingent value right $(CVR)$ of $2 per share
** CVR is tied to a drug that Vigil is developing for the potential treatment of Alzheimer's disease
** Shares of Vigil, which have lost a third of their value in the past 12 months, closed at a valuation of about $100 mln on Wednesday
(Reporting by Medha Singh)
((medha.singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。